Akero Therapeutics, Inc. Overview
Pro stress-test →Akero has been acquired by Novo Nordisk. Akero Therapeutics engages in developing transformational treatments for patients with serious metabolic diseases, with its lead product candidate being efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates metabolism for treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. The company represents a strategic acquisition target in the rapidly growing fatty liver disease treatment market.
Strategic Profile
Pro stress-test →Its lead asset, EFX, an FGF21 analog, represents a scientifically distinct approach compared to some competitors, focusing on addressing the underlying metabolic drivers of the disease alongside liver health. Novo said it would buy Akero for $54 a share in cash and an additional $6 if it gets U.S. approval of Efruxifermin - its treatment for fatty liver disease.
Competitive Landscape
Pro stress-test →Akero is in a sprint with other biotechs and pharma companies to capture a slice of the growing MASH market, currently cornered by Madrigal Pharmaceuticals' first-to-market product Rezdiffra. Akero is on a similar timeline as fellow biotech 89bio, both of which are in Phase 3 studies.
Industry Context
Akero Therapeutics, Inc. operates in Biopharmaceuticals - Metabolic Disease Treatment.
Key facts
Founded: 2017 · Headquarters: South San Francisco, US